351 related articles for article (PubMed ID: 10543428)
1. Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
Varani K; Rizzi A; Calo G; Bigoni R; Toth G; Guerrini R; Gessi S; Salvadori S; Borea PA; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):270-7. PubMed ID: 10543428
[TBL] [Abstract][Full Text] [Related]
2. In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens.
Menzies JR; Glen T; Davies MR; Paterson SJ; Corbett AD
Eur J Pharmacol; 1999 Dec; 385(2-3):217-23. PubMed ID: 10607879
[TBL] [Abstract][Full Text] [Related]
3. Quantitative autoradiographic mapping of the ORL1, mu-, delta- and kappa-receptors in the brains of knockout mice lacking the ORL1 receptor gene.
Clarke S; Chen Z; Hsu MS; Pintar J; Hill R; Kitchen I
Brain Res; 2001 Jul; 906(1-2):13-24. PubMed ID: 11430857
[TBL] [Abstract][Full Text] [Related]
4. Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships.
Varani K; Calo G; Rizzi A; Merighi S; Toth G; Guerrini R; Salvadori S; Borea PA; Regoli D
Br J Pharmacol; 1998 Dec; 125(7):1485-90. PubMed ID: 9884077
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of nociceptin receptor: an in vitro study.
Calò G; Rizzi A; Bodin M; Neugebauer W; Salvadori S; Guerrini R; Bianchi C; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):713-8. PubMed ID: 9276153
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
7. CI-977, a novel and selective agonist for the kappa-opioid receptor.
Hunter JC; Leighton GE; Meecham KG; Boyle SJ; Horwell DC; Rees DC; Hughes J
Br J Pharmacol; 1990 Sep; 101(1):183-9. PubMed ID: 2178014
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide.
Shimohigashi Y; Hatano R; Fujita T; Nakashima R; Nose T; Sujaku T; Saigo A; Shinjo K; Nagahisa A
J Biol Chem; 1996 Sep; 271(39):23642-5. PubMed ID: 8798582
[TBL] [Abstract][Full Text] [Related]
9. [3H]ac-RYYRWK-NH2, a novel specific radioligand for the nociceptin/orphanin FQ receptor.
Thomsen C; Valsborg JS; Platou J; Martin J; Foged C; Johansen NL; Olsen UB; Madsen K
Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):538-45. PubMed ID: 11138846
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors.
Maguire P; Tsai N; Kamal J; Cometta-Morini C; Upton C; Loew G
Eur J Pharmacol; 1992 Mar; 213(2):219-25. PubMed ID: 1355735
[TBL] [Abstract][Full Text] [Related]
11. HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
Lattanzi R; Negri L; Giannini E; Schmidhammer H; Schutz J; Improta G
Br J Pharmacol; 2001 Sep; 134(2):441-7. PubMed ID: 11564664
[TBL] [Abstract][Full Text] [Related]
12. Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs.
Zadina JE; Kastin AJ; Ge LJ; Hackler L
Life Sci; 1994; 55(24):PL461-6. PubMed ID: 7990646
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of dermorphin analogues containing N-substituted amino acids in the 2-position of the peptide sequence.
Schmidt R; Kálmán A; Chung NN; Lemieux C; Horváth C; Schiller PW
Int J Pept Protein Res; 1995 Jul; 46(1):47-55. PubMed ID: 7558596
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells.
Hirota K; Okawa H; Appadu BL; Grandy DK; Devi LA; Lambert DG
Anesthesiology; 1999 Jan; 90(1):174-82. PubMed ID: 9915326
[TBL] [Abstract][Full Text] [Related]
15. Capsaicin inhibits the in vitro binding of peptides selective for mu- and kappa-opioid, and nociceptin-receptors.
Wollemann M; Ioja E; Benyhe S
Brain Res Bull; 2008 Sep; 77(2-3):136-42. PubMed ID: 18588953
[TBL] [Abstract][Full Text] [Related]
16. Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes.
Mignat C; Wille U; Ziegler A
Life Sci; 1995; 56(10):793-9. PubMed ID: 7885194
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
18. Bioactivity of new mu and delta opioid peptides.
Capasso A
Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
[TBL] [Abstract][Full Text] [Related]
19. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.
Gengo PJ; Pettit HO; O'Neill SJ; Wei K; McNutt R; Bishop MJ; Chang KJ
J Pharmacol Exp Ther; 2003 Dec; 307(3):1221-6. PubMed ID: 14534368
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites.
Nicholson JR; Paterson SJ; Menzies JR; Corbett AD; McKnight AT
Can J Physiol Pharmacol; 1998 Mar; 76(3):304-13. PubMed ID: 9673794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
